The companies have yet to disclose how many programs they plan to collaborate on or what indications they will prioritize.

Priority voucher awardees and regulators could feel pressure to “meet the moment” as FDA watchers question the intent and ...

Halda Therapeutics is developing oral assets for prostate and lung cancer. The deal comes after Johnson & Johnson set an ...

Sarepta must also run a post-marketing study for Elevidys to better assess the risk of serious liver injury in patients dosed ...

Artios Pharma is working on a pipeline of oncology assets, led by alnodesertib, currently being tested for second-line ...

Aside from announcing layoffs, Sensei has decided to terminate its R&D work. The biotech has $25 million on hand, and ...

There appears to be growing frustration about FDA Commissioner Marty Makary’s management style within the highest levels of ...

Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...

Merck has made several big-ticket deals this year, led by its $10 billion buyout of Verona Pharma in July, giving the pharma ...

Bayer has let go of about 13,500 employees, including around 5,000 managers, since implementing a new operating model in ...

Altimmune’s pemvidutide showed “class-leading signals” in non-invasive assessments and has “potentially best-in-class ...

Through substantial leadership turnover and workforce cuts, the FDA has continued to support the advanced therapy sector, ...